Clascoterone full results 2026 9/1/2026
Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Whatever happened to Clascoterone? (breezula for hair) (sold as Winlevi for acne available since 2021)
Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.
community Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?
Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.
community Clascoterone might be the Finasteride for female pattern hair loss.
Clascoterone, a topical anti-androgen, shows promise for treating female pattern hair loss without systemic side effects, offering a potential alternative to minoxidil. It could also benefit men who experience side effects from finasteride.
community Clascoterone won't be available until q4 2027 at the earliest per the newest Cosmo Pharma newsletter
Clascoterone won't be available in the US until 2028, with EU filings planned for 2027. It's considered an alternative for those who experience side effects from standard treatments like finasteride and dutasteride.
community Clascoterone Scalp 2 Results in July?
The conversation discusses the anticipation of clascoterone scalp treatment results for hair loss, with concerns about its availability and high cost. Users express hope for positive outcomes and affordable access.
Related Research
6 / 6 resultsresearch Beyond the Follicle: A Narrative Review on How Systemic Diseases and Drugs Affect Alopecia
research Clascoterone: First Approval
This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.
research Use of topical clascoterone for the treatment of hidradenitis suppurativa
This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
research Clascoterone as a novel treatment for androgenetic alopecia
This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.
research Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.